Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease [PDF]
Frontiers in Pharmacology, 2021 Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide. Mineralocorticoid receptor (MR) plays an important role in the development of DKD.
Daiji Kawanami +6 more
doaj +7 more sources
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease [PDF]
European Journal of Heart Failure, 2015 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110733/1/ejhf218 ...
Albert +39 more
core +4 more sources
Mineralocorticoid Receptor Antagonists [PDF]
International Cardiovascular Forum Journal, 2019 Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
+5 more sources
Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy. [PDF]
Redox Biol, 2023 Yao L +8 more
europepmc +2 more sources
Mineralocorticoid Receptor Antagonists in ESKD [PDF]
Clinical Journal of the American Society of Nephrology, 2020 There is an urgent need for interventions that reduce cardiovascular risks in patients with ESKD. Recently there has been considerable interest in whether blocking the effects of the mineralocorticoid aldosterone could be such an intervention.
Adhish, Agarwal, Alfred K, Cheung
openaire +2 more sources
The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study. [PDF]
PLoS ONE, 2014 It has been suggested that mineralocorticoid receptor antagonists have direct cardioprotective properties, because these drugs reduce mortality in patients with heart failure.
T N A van den Berg +5 more
doaj +1 more source
Frontiers in Physiology, 2022 Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production.
Roberto Palacios-Ramirez +10 more
doaj +1 more source
A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
Рациональная фармакотерапия в кардиологии, 2015 The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
B. B. Gegenava, O. M. Drapkina
doaj +3 more sources
Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling [PDF]
, 2015 Type 2 diabetes (DM2) increases the risk of cardiovascular disease. Aldosterone, which has pro-oxidative and pro-inflammatory effects in the cardiovascular system, is positively regulated in DM2.
Bruder-Nascimento, Thiago +7 more
core +3 more sources
Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue [PDF]
Xin yixueObesity is a chronic disease caused by the long-term interaction of multiple environmental factors on a specific genetic background. Among these factors， the overactivation of mineralocorticoid receptors （MR） plays a significant role in adipose tissue ...
WEN Runzhi, WANG Li, ZHAO Naiqian
doaj +1 more source